RAGE Biotech
Julie Monk PhD is a seasoned professional in pharmaceutical development, currently serving as Associate Director of Pharmaceutical Development at RAGE Biotech since April 2024 and as Operations Manager at Resseptor Therapeutics since November 2023. Julie has extensive experience in clinical development, having worked as Senior Clinical Development Coordinator at Monash University from October 2021 to November 2023, and held roles as Senior Medical Writer at Paradigm Biopharmaceuticals and CSL between 2017 and 2021. A graduate of the University of Melbourne with a PhD in Biochemistry and Molecular Biology, Julie's career includes significant contributions as a Medical Writer at ProScribe and Adrenalin Strategics, as well as freelance positions at CSIRO and Altana Pharma.
This person is not in any teams
RAGE Biotech
RAGE Biotech Pty Ltd is a pharmaceutical start-up company developing novel therapeutics for patients with difficult-to-treat inflammatory disease. With our proprietary RNA therapeutics and peptide technologies, we are developing drugs targeting the Receptor for Advanced Glycation End-products (RAGE), a clinically important, pro-inflammatory ‘sensing’ receptor. Our most advanced programme is an inhaled drug for lung diseases where inflammation is a problem. RAGE Biotech was formed in 2020 with investments from IP Group, Monash Investment Holdings, the University of Western Australia and the Perron Instute.